{"filing":{"accession_number":"0001193125-26-366931","cik":"0001628171","ticker":"RVMDW","company_name":"Revolution Medicines, Inc.","form":"8-K","filing_date":"2026-08-26","report_date":"2026-08-26","primary_document":"rvmd-20260826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526366931/rvmd-20260826.htm"},"events":[{"id":29692,"run_id":27204,"accession_number":"0001193125-26-366931","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma, a major regulatory and commercial milestone for Revolution Medicines. This is a material operational event—the product is now available for prescription in the United States—but does not fit the specific named categories (earnings, M\u0026A, impairment, etc.). The approval is based on successful Phase 3 trial data (RASolute 302) and includes pricing information ($39,800 for a 30-day supply), indicating commercial readiness and materiality to investors assessing the company's pipeline and revenue prospects.","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-08-26","form":"8-K","submitted_at":null,"items":[{"id":32068,"accession_number":"0001193125-26-366931","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma, a major regulatory and commercial milestone for Revolution Medicines. This is a material operational event—the product is now available for prescription in the United States—but does not fit the specific named categories (earnings, M\u0026A, impairment, etc.). The approval is based on successful Phase 3 trial data (RASolute 302) and includes pricing information ($39,800 for a 30-day supply), indicating commercial readiness and materiality to investors assessing the company's pipeline and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T17:34:36.859355+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32068,"accession_number":"0001193125-26-366931","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma, a major regulatory and commercial milestone for Revolution Medicines. This is a material operational event—the product is now available for prescription in the United States—but does not fit the specific named categories (earnings, M\u0026A, impairment, etc.). The approval is based on successful Phase 3 trial data (RASolute 302) and includes pricing information ($39,800 for a 30-day supply), indicating commercial readiness and materiality to investors assessing the company's pipeline and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T17:34:36.859355+00:00","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-08-26"}]}